Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Состояние контроля гиперхолестеринемии у больных сахарным диабетом и ишемической болезнью сердца в условиях амбулаторной практики
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Ключевые слова: сахарный диабет, дислипидемия, статины, эффективность терапии.
________________________________________________
In a created dispensary group of diabetic patients of 713 studied, those aged 18 years and over, 5,6% of the patients had type 1 diabetes and in 94,4% of patients were diagnosed with type 2 diabetes (p<0,001). All examined patients had hypertension history. Among patients with coronary artery disease, type 1 diabetes was diagnosed in 18% of patients, 28,6% of whom were receiving statins. Among patients with type 2 diabetes, coronary heart disease was diagnosed in 48% of cases and only 21,3% of patients were receiving statins. The average dose of atorvastatin is 14 mg/day, and simvastatin – 17 mg/day. Patients with type 2 diabetes without CHD received statins in 8,7% of cases in following doses: atorvastatin – 10 mg/day, simvastatin – 21 mg/day. Not more than 3% of diabetic patients regardless of diabetes type have optimal lipid accidental laboratory monitoring. Statin therapy efficacy as well as its coverage in actual clinical practice flow among dispensary diabetic patients group, regardless of disease type approaches zero.
Key words: diabetes mellitus, dyslipidemia, statins, the effectiveness of therapy.
2. Беленков Ю.Н. Хроническая сердечная недостаточность в России – опыт 25 лет: где мы находимся и куда должны идти. Сердечная недостаточность. 2003; 1: 9–11.
3. Российские рекомендации «Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза». Секция атеросклероза ВНОК. Кардиоваскулярная терапия и профилактика. 2004; 2 (Прил.).
4. Scandinavian Simvastatin Survival Stadi Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Skandinavian Simvastatin Survival Stady (4S). Lancet 1994; 344: 1383–9.
5. Eberly LE, Neaton JD, Thomas AJ et al. Multiple-stage screening and mortality in the Multihle Risk Factor Intervention Trial. Clin Trials 2004; 1 (2): 148–61.
6. Callahan AS. 3rd. Vascular pleiotropy of statins: clinical evidence and biochemical mechanisms. Curr Atheroscler Rep 2003; 5 (1): 33–7.
7. Кухарчук В.В., Бубнова М.Г., Кательницкая Л.И. и др. Эффективность и безопастность симвастатина у пациентов с гиперхолестеринемией (результаты многоцентрового клинического исследования). Кардиология. 2003; 5 (43): 42–7.
8. Рудакова А.В. Нужны ли статины в стационарах? Фармакоэкономический аспект проблемы. Атмосфера. Кардиология. 2004; 1.
9. De Backer G, Ambrosioni E, Borch-Johnsen K et al. Third Joint Task Force of the European and other Societies. European Guidelines on Cardiovascular Disease Prevention. Eur J Cardiovasc Preven Rehab 2003; 10 (Suppl. 1): S1–S78.
10. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the management of diabetes mellitus. Endocrine practice vol 13 (Suppl. 1) May/June 2007.
11. De Backer G, Ambrosioni E, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of the European and other societies on Cardiovascular Disease Prevention in Clinical practice. Executive Summary. Eur Heart J 2003; 24:1601–10.
12. Kharlip J, Naglieri R, Mitchell BD et al. Screening for silent coronary heart disease in type 2 diabetes: clinical application of American Diabetes Association guidelines. Diabetes Care 2006; 29: 692–4.
ГБОУ ВПО Нижегородская государственная медицинская академия Минздрава России
*fomin-i@yandex.ru
________________________________________________
F.Yu.Valikulova, I.V.Fomin*, L.A.Mudrova, A.R.Vaysberg
Nizhny Novgorod State Medical Academy
*fomin-i@yandex.ru